We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Almac Sciences, a member of the Almac Group, has expanded its biologics testing laboratory with significant investment in mass spectrometry equipment.
Researchers have identified 27 biomarkers that could be used to predict the course of SARS-CoV-2 infection and whether a patient with COVID-19 will become severely ill.
A team of UK biotech experts say they are close to delivering a “sophisticated and affordable testing technology” that will complement COVID-19 tests already in use.